DK1991584T3 - Antistoffer mod human IL-22 og anvendelser deraf - Google Patents

Antistoffer mod human IL-22 og anvendelser deraf

Info

Publication number: DK1991584T3
Authority: DK; Denmark
Prior art keywords: antibodies; human
Prior art date: 2006-02-21

Application number

DK07751204.4T

Other languages

English (en)

Inventor

Jing Li

Davinder S Gill

Geertruida M Veldman

Lynette A Fouser

Viia Valge-Archer

David C Lowe

Caroline S Russell

Suzanne E Cohen

Albert B Thom

Ralph R Minter

Original Assignee

Wyeth Llc

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-21

Filing date

2007-02-21

Publication date

2012-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1991584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-02-21 Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc

2012-04-02 Application granted granted Critical

2012-04-02 Publication of DK1991584T3 publication Critical patent/DK1991584T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK07751204.4T 2006-02-21 2007-02-21 Antistoffer mod human IL-22 og anvendelser deraf DK1991584T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77459606P	2006-02-21	2006-02-21
PCT/US2007/004430 WO2007098170A1 (en)	2006-02-21	2007-02-21	Antibodies against human il-22 and uses therefor

Publications (1)

Publication Number	Publication Date
DK1991584T3 true DK1991584T3 (da)	2012-04-02

Family

ID=38236225

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15184078.2T DK3020729T3 (da)	2006-02-21	2007-02-21	Antistoffer mod human il-22 og anvendelser deraf
DK07751204.4T DK1991584T3 (da)	2006-02-21	2007-02-21	Antistoffer mod human IL-22 og anvendelser deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15184078.2T DK3020729T3 (da)	2006-02-21	2007-02-21	Antistoffer mod human il-22 og anvendelser deraf

Country Status (32)

Country	Link
US (4)	US7901684B2 (da)
EP (3)	EP1991584B1 (da)
JP (1)	JP5150516B2 (da)
KR (2)	KR20080113214A (da)
CN (1)	CN101426816B (da)
AR (1)	AR059604A1 (da)
AT (1)	ATE538137T1 (da)
AU (1)	AU2007217751B2 (da)
BR (1)	BRPI0708101B8 (da)
CA (1)	CA2643226C (da)
CR (1)	CR10237A (da)
DK (2)	DK3020729T3 (da)
EC (1)	ECSP088751A (da)
ES (2)	ES2738731T3 (da)
HK (1)	HK1120813A1 (da)
HN (1)	HN2008001292A (da)
HU (1)	HUE044595T2 (da)
IL (1)	IL193605A (da)
MX (2)	MX337778B (da)
MY (1)	MY146664A (da)
NO (1)	NO20083715L (da)
NZ (1)	NZ570878A (da)
PE (1)	PE20080111A1 (da)
PL (2)	PL3020729T3 (da)
PT (2)	PT1991584E (da)
RU (1)	RU2467016C2 (da)
SA (1)	SA07280062B1 (da)
SG (1)	SG172628A1 (da)
SI (2)	SI1991584T1 (da)
TW (1)	TWI417301B (da)
WO (1)	WO2007098170A1 (da)
ZA (1)	ZA200807278B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60036937T2 (de) *	1999-04-28	2008-08-07	Genetics Institute, LLC, Cambridge	HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE
NZ712762A (en) *	2005-12-02	2017-03-31	Genentech Inc	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
RU2011105466A (ru) *	2008-08-28	2012-10-10	ВАЙЕТ ЭлЭлСи (US)	Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
EP2419733A4 (en)	2009-04-13	2013-12-25	Univ Leland Stanford Junior	METHODS AND DEVICES FOR DETECTING THE PRESENCE OF AN ANALYTE IN A SAMPLE
AU2010291985B2 (en)	2009-09-14	2016-05-05	The Regents Of The University Of Colorado	Modulation of yeast-based immunotherapy products and responses
CN106198715B (zh) *	2010-03-12	2020-01-10	小利兰·斯坦福大学托管委员会	基于磁性传感器的定量结合动力学分析
WO2011139974A2 (en) *	2010-05-03	2011-11-10	Abbott Laboratories	Anti-pai-1 antibodies and methods of use thereof
CN103382223B (zh) *	2012-04-01	2015-06-10	上海益杰生物技术有限公司	针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9221904B2 (en) *	2012-07-19	2015-12-29	National Cheng Kung University	Treatment of osteoarthritis using IL-20 antagonists
CN104583238A (zh) *	2012-08-31	2015-04-29	阿尔金-X有限公司	用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
EA035645B1 (ru)	2013-03-15	2020-07-21	Дженентек, Инк.	ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
CN105139918B (zh) *	2015-06-26	2017-04-12	哈尔滨工业大学	一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) *	2016-02-22	2019-01-18	王晨辉	一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) *	2016-08-22	2018-03-01	Medimmune, Llc	Binding molecules specific for notch4 and uses thereof
EP3546943A4 (en) *	2016-11-24	2020-09-16	Huvet Bio, Inc.	DIAGNOSIS OF DISEASES
TWI776827B (zh)	2016-11-28	2022-09-11	日商中外製藥股份有限公司	能夠調節配體結合活性的配體結合分子
WO2018097307A1 (ja)	2016-11-28	2018-05-31	中外製薬株式会社	抗原結合ドメインおよび運搬部分を含むポリペプチド
AU2018377783A1 (en)	2017-11-28	2020-06-11	Chugai Seiyaku Kabushiki Kaisha	Polypeptide including antigen-binding domain and carrying section
TW202402792A (zh)	2017-11-28	2024-01-16	日商中外製藥股份有限公司	可調整配體結合活性的配體結合分子
KR102536314B1 (ko) *	2018-05-23	2023-05-25	주식회사 휴벳바이오	질환의 진단용 조성물
US11834472B2 (en)	2018-06-05	2023-12-05	Bioatla, Inc.	Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7323608B2 (ja) *	2018-10-11	2023-08-08	アリヴィオセラピューティクス，インコーポレイテッド	スマート放出のための非注射用ヒドロゲル製剤
KR102226826B1 (ko) *	2020-08-06	2021-03-11	주식회사 휴벳바이오	버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
AR125581A1 (es)	2020-12-07	2023-08-02	UCB Biopharma SRL	Anticuerpos multiespecíficos y combinaciones de anticuerpos
AU2021398385A1 (en)	2020-12-07	2023-07-13	UCB Biopharma SRL	Antibodies against interleukin-22
EP4301777A1 (en)	2021-03-02	2024-01-10	Dana-Farber Cancer Institute, Inc.	Methods of treating red blood cell disorders
WO2023110942A1 (en)	2021-12-14	2023-06-22	Charité-Universitätsmedizin Berlin	Prevention of impaired fracture healing

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US6018026A (en)	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en)	1988-01-22	1998-05-12	Zymogenetics, Inc.	Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP1997891A1 (en)	1988-09-02	2008-12-03	Dyax Corporation	Generation and selection of recombinant varied binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8905669D0 (en)	1989-03-13	1989-04-26	Celltech Ltd	Modified antibodies
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
GB9021679D0 (en)	1990-10-05	1990-11-21	Gorman Scott David	Antibody preparation
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja)	1991-03-01	2008-09-10	ダイアックスコープ．	小型タンパク質
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
US5833976A (en) *	1991-08-06	1998-11-10	Schering Corporation	Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
GB9214857D0 (en)	1992-07-13	1992-08-26	Medical Res Council	Human nucleic acid fragments and their use
EP0656946B2 (en)	1992-08-21	2010-03-31	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US5789192A (en)	1992-12-10	1998-08-04	Schering Corporation	Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) *	1993-04-07	1996-07-16	Genetics Institute, Inc.	Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
AU6796094A (en)	1993-04-29	1994-11-21	Raymond Hamers	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5674487A (en) *	1994-09-28	1997-10-07	Univ Jefferson	Method for treating autoimmune diseases
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
PT859841E (pt)	1995-08-18	2002-11-29	Morphosys Ag	Bibliotecas de proteinas/ (poli) peptidos
BRPI9707379C8 (pt)	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
AU2576697A (en) *	1996-04-19	1997-11-12	Chugai Seiyaku Kabushiki Kaisha	Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
CA2258518C (en)	1996-06-27	2011-11-22	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6492507B1 (en) *	1996-10-23	2002-12-10	Incyte Genomics, Inc.	Polynucleotides encoding human eosinophil-derived basic protein
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
WO2002016611A2 (en)	2000-08-24	2002-02-28	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) *	1999-12-07	2003-04-22	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030032057A1 (en) *	1997-08-26	2003-02-13	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6350892B1 (en)	1997-09-23	2002-02-26	Bristol-Myers Squibb Company	Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
ES2386262T3 (es) *	1998-01-23	2012-08-14	F. Hoffmann-La Roche Ag	Anticuerpos contra IL-12 humana
US20010023070A1 (en) *	1998-05-29	2001-09-20	Reinhard Ebner	Interleukins-21 and 22
AU4208799A (en) *	1998-05-29	1999-12-13	Human Genome Sciences, Inc.	Interleukins-21 and 22
US6274710B1 (en) *	1998-10-26	2001-08-14	Ludwig Institute For Cancer Research	Antibodies which specifically bind T Cell inducible factors (TIFs)
US6331613B1 (en) *	1998-10-26	2001-12-18	Ludwig Institue For Cancer Research	Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
US7081528B2 (en) *	1998-10-26	2006-07-25	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules encoding T cell derived inducible factors
AU776910B2 (en)	1998-12-08	2004-09-23	Merck Patent Gesellschaft Mit Beschrankter Haftung	Modifying protein immunogenicity
JP4841038B2 (ja)	1999-03-25	2011-12-21	アボットゲーエムベーハーウントカンパニーカーゲー	ヒトｉｌ−１２に結合するヒト抗体およびその産生法
US7307161B1 (en) *	1999-04-28	2007-12-11	Genetics Institute, Llc	Human Gil-19/AE289 polynucleotides
US6939545B2 (en) *	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
WO2000070049A2 (en)	1999-05-19	2000-11-23	Incyte Genomics, Inc.	Extracellular signaling molecules
WO2000073457A1 (en)	1999-05-27	2000-12-07	Schering-Corporation	Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1208195A2 (en)	1999-06-15	2002-05-29	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003534773A (ja) *	1999-12-03	2003-11-25	ザイモジェネティクス，インコーポレイティド	ヒトサイトカイン受容体
US20030170823A1 (en) *	1999-12-23	2003-09-11	Presnell Scott R.	Novel cytokine ZCYTO18
CA2395369C (en)	1999-12-23	2014-07-08	Zymogenetics, Inc.	Cytokine zcyto18
AU2001233034A1 (en)	2000-01-27	2001-08-07	American Cyanamid Company	Method for preparing alpha-sulfonyl hydroxamic acid derivatives
SK12942002A3 (sk) *	2000-02-10	2003-05-02	Abbott Laboratories	Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
EP1806404B1 (en)	2000-07-27	2010-08-18	Wyeth LLC	Use of IL-10 receptor beta antagonistic antibodies for inhibiting IL-TIF/IL-21 induction of acute phase proteins
US20030012788A1 (en) *	2000-07-27	2003-01-16	Jean-Christophe Renauld	Method for influencing kinase pathways with IL-22
US7094570B2 (en) *	2003-03-11	2006-08-22	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
AU2002252097A2 (en)	2001-02-23	2002-09-12	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
US7638604B2 (en) *	2001-02-23	2009-12-29	Genetics Institute, Llc	Monoclonal antibodies against interleukin-22
US20040058445A1 (en)	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en)	2001-09-10	2002-12-12	Nagem Ronaldo Alves Pinto	Crystal structure of human interleukin-22
AU2003223344B9 (en)	2002-03-22	2009-07-16	Zymogenetics, Inc.	Anti-IL-TIF antibodies and methods of using in inflammation
CA2484121A1 (en) *	2002-05-01	2003-11-13	Human Genome Sciences, Inc.	Antibodies that specifically bind to chemokine beta-4
US6921538B2 (en) *	2002-05-10	2005-07-26	Allergan, Inc.	Therapeutic treatments for neuropsychiatric disorders
RU2006101702A (ru) *	2003-06-23	2006-09-10	Дженетикс Инститьют, Ллс (Us)	Антитела против интерлейкина-22 и их применения
WO2007004788A1 (en)	2005-07-04	2007-01-11	Samsung Electronics Co., Ltd.	Position measuring system and method using wireless broadband (wibro) signal
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
US8359965B2 (en)	2007-09-17	2013-01-29	Oxford J Craig	Apparatus and method for broad spectrum radiation attenuation

2007
- 2007-02-16 TW TW096106166A patent/TWI417301B/zh active
- 2007-02-20 US US11/708,061 patent/US7901684B2/en active Active
- 2007-02-21 EP EP07751204A patent/EP1991584B1/en active Active
- 2007-02-21 SI SI200730795T patent/SI1991584T1/sl unknown
- 2007-02-21 DK DK15184078.2T patent/DK3020729T3/da active
- 2007-02-21 RU RU2008134137/10A patent/RU2467016C2/ru active
- 2007-02-21 KR KR1020087023020A patent/KR20080113214A/ko active Search and Examination
- 2007-02-21 PT PT07751204T patent/PT1991584E/pt unknown
- 2007-02-21 KR KR1020147021161A patent/KR101616712B1/ko active Active
- 2007-02-21 NZ NZ570878A patent/NZ570878A/en unknown
- 2007-02-21 PL PL15184078T patent/PL3020729T3/pl unknown
- 2007-02-21 SA SA07280062A patent/SA07280062B1/ar unknown
- 2007-02-21 AT AT07751204T patent/ATE538137T1/de active
- 2007-02-21 CA CA2643226A patent/CA2643226C/en active Active
- 2007-02-21 SI SI200732116T patent/SI3020729T1/sl unknown
- 2007-02-21 DK DK07751204.4T patent/DK1991584T3/da active
- 2007-02-21 PE PE2007000189A patent/PE20080111A1/es active IP Right Grant
- 2007-02-21 MY MYPI20083190A patent/MY146664A/en unknown
- 2007-02-21 PL PL07751204T patent/PL1991584T3/pl unknown
- 2007-02-21 PT PT15184078T patent/PT3020729T/pt unknown
- 2007-02-21 EP EP15184078.2A patent/EP3020729B1/en active Active
- 2007-02-21 EP EP11188458.1A patent/EP2431392B1/en not_active Withdrawn - After Issue
- 2007-02-21 ES ES15184078T patent/ES2738731T3/es active Active
- 2007-02-21 WO PCT/US2007/004430 patent/WO2007098170A1/en active Application Filing
- 2007-02-21 MX MX2013009826A patent/MX337778B/es unknown
- 2007-02-21 JP JP2008556389A patent/JP5150516B2/ja active Active
- 2007-02-21 BR BRPI0708101A patent/BRPI0708101B8/pt active IP Right Grant
- 2007-02-21 AU AU2007217751A patent/AU2007217751B2/en active Active
- 2007-02-21 SG SG2011037538A patent/SG172628A1/en unknown
- 2007-02-21 ES ES07751204T patent/ES2377463T3/es active Active
- 2007-02-21 HU HUE15184078 patent/HUE044595T2/hu unknown
- 2007-02-21 MX MX2008010708A patent/MX2008010708A/es active IP Right Grant
- 2007-02-21 CN CN2007800140240A patent/CN101426816B/zh active Active
- 2007-02-22 AR ARP070100742A patent/AR059604A1/es active IP Right Grant
2008
- 2008-08-20 HN HN2008001292A patent/HN2008001292A/es unknown
- 2008-08-21 IL IL193605A patent/IL193605A/en active IP Right Grant
- 2008-08-22 CR CR10237A patent/CR10237A/es unknown
- 2008-08-22 ZA ZA200807278A patent/ZA200807278B/xx unknown
- 2008-08-28 NO NO20083715A patent/NO20083715L/no not_active Application Discontinuation
- 2008-09-19 EC EC2008008751A patent/ECSP088751A/es unknown
2009
- 2009-01-06 HK HK09100101.7A patent/HK1120813A1/xx unknown
- 2009-05-29 US US12/474,644 patent/US8187603B2/en active Active
2010
- 2010-01-29 US US12/696,434 patent/US8182817B2/en active Active
2012
- 2012-05-22 US US13/477,717 patent/US8470993B2/en active Active

Also Published As

Publication number	Publication date
US8182817B2 (en)	2012-05-22
KR20140100589A (ko)	2014-08-14
TW200801041A (en)	2008-01-01
BRPI0708101B1 (pt)	2020-01-14
JP2009531023A (ja)	2009-09-03
CA2643226C (en)	2016-04-12
AU2007217751A1 (en)	2007-08-30
CN101426816B (zh)	2012-12-12
HK1120813A1 (en)	2009-04-09
PL1991584T3 (pl)	2012-05-31
RU2467016C2 (ru)	2012-11-20
MX337778B (es)	2016-03-18
NO20083715L (no)	2008-11-06
EP1991584B1 (en)	2011-12-21
SI1991584T1 (sl)	2012-05-31
RU2008134137A (ru)	2010-03-27
SG172628A1 (en)	2011-07-28
ATE538137T1 (de)	2012-01-15
BRPI0708101B8 (pt)	2021-05-25
AU2007217751B2 (en)	2012-08-23
IL193605A (en)	2015-07-30
EP3020729A1 (en)	2016-05-18
HUE044595T2 (hu)	2019-11-28
MY146664A (en)	2012-09-14
SI3020729T1 (sl)	2019-10-30
NZ570878A (en)	2011-09-30
MX2008010708A (es)	2008-11-14
ZA200807278B (en)	2009-05-27
PE20080111A1 (es)	2008-02-20
KR20080113214A (ko)	2008-12-29
US20070243589A1 (en)	2007-10-18
US8470993B2 (en)	2013-06-25
CR10237A (es)	2008-11-26
ES2377463T3 (es)	2012-03-27
US7901684B2 (en)	2011-03-08
KR101616712B1 (ko)	2016-04-29
JP5150516B2 (ja)	2013-02-20
US20110275790A1 (en)	2011-11-10
TWI417301B (zh)	2013-12-01
US20130005033A1 (en)	2013-01-03
ECSP088751A (es)	2008-11-27
ES2738731T3 (es)	2020-01-24
SA07280062B1 (ar)	2012-03-13
PL3020729T3 (pl)	2019-12-31
AR059604A1 (es)	2008-04-16
PT3020729T (pt)	2019-08-06
US8187603B2 (en)	2012-05-29
EP3020729B1 (en)	2019-06-26
DK3020729T3 (da)	2019-07-29
CA2643226A1 (en)	2007-08-30
PT1991584E (pt)	2012-02-20
EP2431392B1 (en)	2015-09-09
EP1991584A1 (en)	2008-11-19
CN101426816A (zh)	2009-05-06
HN2008001292A (es)	2012-02-13
WO2007098170A1 (en)	2007-08-30
BRPI0708101A8 (pt)	2019-01-22
EP2431392A1 (en)	2012-03-21
IL193605A0 (en)	2011-08-01
US20100184960A1 (en)	2010-07-22
BRPI0708101A2 (pt)	2011-05-17

Publication	Publication Date	Title
DK1991584T3 (da)	2012-04-02	Antistoffer mod human IL-22 og anvendelser deraf
DK2129396T3 (da)	2013-11-25	Antistoffer mod ErbB3 og anvendelser deraf
DK3187506T3 (da)	2019-06-11	Antistoffer mod IL-6 og anvendelse deraf
DK2327423T3 (da)	2019-12-16	Humane antistoffer mod humant interleukin-22 (IL-22)
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
DK1937276T3 (da)	2013-02-11	Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK2222706T3 (da)	2014-07-07	Antibodies against human nkg2d and uses thereof
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
DK2474557T3 (da)	2014-11-10	Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
DK2147096T3 (da)	2015-06-15	Modificerede faktor-VII-polypeptider og anvendelser deraf
DK2032606T3 (da)	2014-02-03	Antistoffer og immunkonjugater og anvendelser deraf
DK2220320T3 (da)	2019-11-04	Forseglet enhed og mellemstykke
DK1996621T3 (da)	2010-04-19	Antistoffer mod beta-amyloid-peptid
DK2913344T3 (da)	2017-11-06	Specifikke bindingsproteiner og anvendelser deraf
DK2185164T3 (da)	2017-11-13	Sammensætning og terapeutisk antitumorvaccine
DK3338799T3 (da)	2021-06-14	Antistoffer til il-6 og anvendelse deraf
NO20080692L (no)	2008-04-03	SP35 antistoffer og anvendelse derav
DK1838733T3 (da)	2011-11-28	Antistoffer rettet mod angiopoietin-2 og anvendelser deraf
DK2068887T3 (da)	2014-05-19	SP35-antistoffer og anvendelser heraf
DK2170827T3 (da)	2013-11-18	Indolin-2-oner og aza-indolin-2-oner
DK2328931T3 (da)	2013-09-30	Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
DK2029799T3 (da)	2012-12-10	Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK2096167T3 (da)	2013-02-04	Aptamer mod midkin og anvendelse deraf